SRR602728
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- OXIDATIVE_PHOSPHORYLATION+0.333
- HEDGEHOG_SIGNALING+0.248
- KRAS_SIGNALING_DN+0.247
- SPERMATOGENESIS+0.163
- MYOGENESIS+0.159
- PANCREAS_BETA_CELLS+0.142
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.111
- PI3K_AKT_MTOR_SIGNALING+0.072
- UV_RESPONSE_DN+0.048
- APICAL_JUNCTION+0.046
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.634
- IL6_JAK_STAT3_SIGNALING-0.577
- INTERFERON_GAMMA_RESPONSE-0.575
- TNFA_SIGNALING_VIA_NFKB-0.506
- ALLOGRAFT_REJECTION-0.471
- INFLAMMATORY_RESPONSE-0.460
- E2F_TARGETS-0.415
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.412
- G2M_CHECKPOINT-0.379
- ANGIOGENESIS-0.371
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR602704 | GTEX | — | 0.981 |
| 2 | SRR1317344 | GTEX | — | 0.979 |
| 3 | SRR1390601 | GTEX | — | 0.978 |
| 4 | SRR1459718 | GTEX | — | 0.977 |
| 5 | SRR1389979 | GTEX | — | 0.974 |
| 6 | SRR1084842 | GTEX | — | 0.972 |
| 7 | SRR1500753 | GTEX | — | 0.971 |
| 8 | SRR1474553 | GTEX | — | 0.968 |
| 9 | SRR1354446 | GTEX | — | 0.968 |
| 10 | SRR821549 | GTEX | — | 0.964 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| OXIDATIVE_PHOSPHORYLATION | 0.333 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.248 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.247 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.163 | Inavolisib | — uncovered |
| MYOGENESIS | 0.159 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.142 | Cobimetinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.111 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.072 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.048 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.046 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.046 | Temsirolimus | — uncovered |
| PEROXISOME | 0.030 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.021 | Remibrutinib | — uncovered |
| APICAL_SURFACE | 0.017 | Temsirolimus | — uncovered |